Integrative Therapiemöglichkeiten des inoperablen Pankreaskarzinoms – eine Übersicht

Matthes, Harald; Buchwald, Dirk; Kröz, Matthias; Schad, F.

doi:10.1055/s-0028-1082599

Cited by 6 publications

(5 citation statements)

References 5 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…[60][61][62][63][64] Even complete remission was documented in patients with different cancer localities. [65][66][67][68] In the initial study, which documented intratumoral application of mistletoe in 14 patients with pancreatic cancer, 38 a tumor response rate of 57% and a local tumor control rate in 93% were reported. In the present follow-up data, we did not have sufficient information on the local response rate, which, as an outcome parameter, has been questioned for some tumors, such as pancreatic carcinoma, 69 due to early local spreading.…”

Section: Discussionmentioning

confidence: 99%

“…cancer, 38 a tumor response rate of 57% and a local tumor control rate in 93% were reported. In the present follow-up data, we did not have sufficient information on the local response rate, which, as an outcome parameter, has been questioned for some tumors, such as pancreatic carcinoma, 69 due to early local spreading.…”

Section: Discussionmentioning

confidence: 99%

“…16,17,[33][34][35][36][37] In a study by Matthes et al, in which 14 pancreatic cancer patients received mistletoe therapy intratumorally, clinical benefits were demonstrated, such as tumor regression (57%), stable disease (36%), and 1-year survival rate (36%), with an overall good tolerance of the treatment. 38 As a next step, we analyzed in this retrospective study all patients with unresectable or metastasized pancreas carcinoma from the Hospital Havelhoehe in Berlin, Germany, and the associated outpatient care center who were treated with intratumoral mistletoe applications. We documented all therapies that were received and analyzed patients' survival.…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Intratumoral Mistletoe (Viscum album L) Therapy in Patients With Unresectable Pancreas Carcinoma

et al. 2013

Self Cite

View full text Add to dashboard Cite

Pancreatic carcinoma remains one of the main causes for cancer-related death. Intratumoral application of anticancer agents is discussed as a promising method for solid tumors such as pancreatic cancer. Endoscopic ultrasound provides a good tool to examine and treat the pancreas. European mistletoe (Viscum album L) is a phytotherapeutic commonly used in integrative oncology in Central Europe. Its complementary use seeks to induce immunostimulation and antitumoral effects as well as alleviate chemotherapeutic side effects. Intratumoral mistletoe application has induced local tumor response in various cancer entities. This off-label use needs to be validated carefully in terms of safety and benefits. Here we report on 39 patients with advanced, inoperable pancreatic cancer, who received in total 223 intratumoral applications of mistletoe, endoscopic ultrasound guided or under transabdominal ultrasound control. No severe procedure-related events were reported. Adverse drug reactions were mainly increased body temperature or fever in 14% and 11% of the applications, respectively. Other adverse drug reactions, such as pain or nausea, occurred in less than 7% of the procedures. No severe adverse drug reaction was recorded. Patients received standard first-and second-line chemotherapy and underwent adequate palliative surgical interventions as well as additive subcutaneous and partly intravenous mistletoe application. A median survival of 11 months was observed for all patients, or 11.8 and 8.3 months for stages III and IV, respectively. Due to the multimodal therapeutic setting and the lack of a control group, the effect of intratumoral mistletoe administration alone remains unclear. This retrospective analysis suggests that intratumoral-applicated mistletoe might contribute to improve survival of patients with pancreatic cancer. In conclusion, the application is feasible and safe, and its efficacy should be evaluated in a randomized controlled trial.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Intratumoral Mistletoe (Viscum album L) Therapy in Patients With Unresectable Pancreas Carcinoma

et al. 2013

Self Cite

View full text Add to dashboard Cite

show abstract

“…Ferner erfolgt in manchen Untersuchungen keine Randomisierung. Diese wird von Befürwortern häufig abgelehnt, da sie keine ganzheitliche Betrachtung der Therapie ermögliche [4,5,6].…”

Section: S 15unclassified

Misteln in der Krebstherapie

Umbreit¹

2011

Dtsch med Wochenschr

View full text Add to dashboard Cite

show abstract

“…AM is a typical representative of integrative medicine, which integrates conventional and complementary therapeutic methods into an overall concept, taking into account the biological-living, psychosocial and spiritual dimensions of the human being in diagnosis and therapy [ 32 ]. The basis of AM is a positive concept of health [ 33 ] with the ability of the human being on the different levels to self-regulate (with hygio-, saluto- and autogenesis) [ 34 ]. According to the level of self-regulation, the various anthroposophical therapies are applied (hygiogenesis: phythotherapeutics, anthroposophics, manual therapies/rhythmic massages, baths, wraps, rubs, eurythmy etc.…”

Section: Introductionmentioning

confidence: 99%

New multimodal intervention to reduce irritable bowel syndrome (IBS) severity symptoms—Pilot study with a 12 month follow-up

Hinse

Thronicke²,

Berghöfer³

et al. 2022

PLoS ONE

View full text Add to dashboard Cite

Introduction Irritable bowel syndrome (IBS) is characterized by patients’ high level of suffering. Up to 60% of patients with IBS have symptoms of anxiety or depression and only little attention has been paid to their specific requirements. Anthroposophical multimodal therapy (AMT) has been shown to significantly improve health-related quality of life of patients with high symptomatic burden. Objective The aim of this pilot study was to find out whether AMT meets the needs of IBS patients and the interactions of AMT with IBS, depression and anxiety Methods Patients with diagnosed IBS were included in a feasibility study and received 12 sessions of AMT over 8 weeks (drks.de, DRKS00016890). The primary endpoint was the change of the IBS severity score (IBS-SSS) and changes were calculated by linear mixed effects analyses. The secondary endpoints were changes of self-reported PHQ-9 and GAD-7 for mental comorbidity as well as self-valued effectiveness and satisfaction of AMT. Results Thirty-six patients, 89% female, were included in the study. AMT was successfully applied to IBS patients (-45 points in the IBS-SSS, p < .05). AMT had a large positive effect (-84 points in IBS-SSS, p < .003) on patients without anxiety or depression. Over time, patients with higher anxiety scores worsened with regard to their IBS compared to patients with depression and without mental comorbidity. The AMT effect was maintained at a 12 month follow up and both mentally affected and unaffected patients, had even lower IBS severity than shortly after AMT. AMT modules were rated by IBS patients as very effective. Conclusion Our findings suggest that an 8-week program of AMT improves the severity of IBS with an ongoing effect at a 12 month follow-up. Especially for patients without psychological comorbidities, AMT is very successful. Future IBS therapies should incorporate a modified multimodal concept with stronger psychological therapy modules in parallel for patients with depression and anxiety.

show abstract

Integrative Therapiemöglichkeiten des inoperablen Pankreaskarzinoms – eine Übersicht

Cited by 6 publications

References 5 publications

Intratumoral Mistletoe (Viscum album L) Therapy in Patients With Unresectable Pancreas Carcinoma

Intratumoral Mistletoe (Viscum album L) Therapy in Patients With Unresectable Pancreas Carcinoma

Misteln in der Krebstherapie

New multimodal intervention to reduce irritable bowel syndrome (IBS) severity symptoms—Pilot study with a 12 month follow-up

Contact Info

Product

Resources

About